Vector Vest Analysis -- CXR's value is $126 CAD
I think CIBC is a little off..... Company Information Business: Concordia Healthcare Corp., formerly Mercari Acquisition Corp., is an integrated, specialty healthcare company focused on the acquisition of pharmaceutical products and medical devices and the acquisition and/or development of orphan drugs. The Company's pharmaceutical business consists of an ADHD-treatment drug, Kapvay(R) (clonidine extended release tablets), a Head Lice Treatment, Ulesfia(R) (benzyl alcohol) Lotion, and an Asthma-related medication, Orapred ODT(R) (prednisolone sodium phosphate orally disintegrating tablets). Capital Appreciation Value: Value is a measure of a stock's current worth. CXR has a current Value of $126.04 per share. Therefore, it is undervalued compared to its Price of $50.95 per share. Value is computed from forecasted earnings per share, forecasted earnings growth, profitability, interest, and inflation rates. Value increases when earnings, earnings growth rate and profitability increase, and when interest and inflation rates decrease. VectorVest advocates the purchase of undervalued stocks. At some point in time, a stock's Price and Value always will converge. RV (Relative Value): RV is an indicator of long-term price appreciation potential. CXR has an RV of 1.75, which is excellent on a scale of 0.00 to 2.00. This indicator is far superior to a simple comparison of Price and Value because it is computed from an analysis of projected price appreciation three years out, AAA Corporate Bond Rates, and risk. RV solves the riddle of whether it is preferable to buy High growth, High P/E stocks, or Low growth, Low P/E stocks. VectorVest favors the purchase of stocks with RV ratings above 1.00.